Epstein-Barr virus (EBV) infection is associated with many human neoplasms, in which EBV-derived latent membrane protein-1 (LMP1) appears to be critical, but its exact oncogenic mechanism remains to be defined. To this end, our initial microarray analyses identified a LMP1-inducible gene, Ugene, originally characterized as a binding partner for uracil DNA glycosylase 2, which is highly expressed in malignant colon cancer. In this report, it was found that Ugene, designated herein as LMP1-induced protein (LMPIP), was induced, in a time-dependent manner, in EBV-infected peripheral blood mononuclear cells and LMP1-transfected 293 cells. Functionally, when compared with mock-transfected cells, overexpression of LMPIP in nasopharyngeal carcinoma (NPC) cell lines resulted in a decrease in reactive oxygen species production and maintained mitochondria membrane potential (Dw) loss induced by H 2 O 2 . The NPC cells transfected with LMPIP also showed a decrease in G1 population and an increase in the cell population in sub-G1 and multiploid phase, concomitant with increased levels of cell cycle activators, including cyclin D1 and CDK4. In contrast, silencing of LMPIP expression in the NPC tumor cell lines with short hairpin RNA interference revealed significantly decreased cell population at G1/S phase, while the number of cells in multiploid phase increased. Significantly, NPC cells with LMPIP knock-down also showed a decrease in tumorigenic and transforming activity induced by ectopic LMP1 expression, as determined by analyses of soft agar foci and tumor size in nude mice. Further, elevated LMPIP expression was also noted in cytoplasm and nuclei in EBVinfected NPC tumor cell mass and non-EBV-infected tumor cell lines. These results suggested that LMPIP may have an important mediator role in EBV-mediated neoplasm and may serve as a new target for therapy of tumors induced by EBV infection.
Introduction
Epstein-Barr virus (EBV), a prototype gamma herpes virus, was the first virus to be associated with human neoplasm, and infects a majority of the population worldwide (Thorley-Lawson and Allday, 2008) . It has been implicated in the pathogenesis and tumor progression in several human malignancies, including Burkitt's and Hodgkin's lymphomas, gastric carcinoma and nasopharyngeal carcinoma (NPC) (Lindahl et al., 1974; Kis et al., 2006; Queiroga et al., 2008) . EBV infection is mainly characterized by the expression of latent genes including nuclear antigens (EBNAs), latent membrane proteins (LMPs) and EBV-encoded RNA (EBER) (Munz and Moormann, 2008; Thorley-Lawson and Allday, 2008) under strict, host-cell-dependent transcriptional control. LMP1 was the first EBV latent gene found to be able to transform cell lines and alter the phenotype of cells because of its oncogenic potential. In human epithelial cells, LMP1 alters many functional properties, such as oxidative stress generation, which are involved in tumor progression and invasion (Pai and Khanna, 2001; Thorley-Lawson and Allday, 2008) . Activation of different signal transduction pathways mediates various downstream pathological effects of LMP1 expression, including cell proliferation, antiapoptosis and metastasis (Pai and Khanna, 2001) .
LMP1 functions as a constitutively active tumor necrosis factor receptor by resembling CD40, which activates a number of signaling pathways in a ligandindependent manner (Pai and Khanna, 2001; Kieser, 2008) . Three distinct functional domains have been identified within the C-terminal regions (amino acids 187-386): C-terminal activation regions 1, 2 and 3 (CTAR 1, CTAR2 and CTAR3). CTAR1 (amino acids 194-231) has been shown to initiate cell proliferation, whereas CTAR2 (amino acids 351-386) is essential for permanent lymphoblastic cell line (LCL) outgrowth (Eliopoulos and Rickinson, 1998; Eliopoulos and Young, 2001) . CTAR3 is a recently identified additional region between the CTAR1 and CTAR2 regions (Kieser, 2008) . In spite of many signaling pathways that have been shown to be involved in the LMP1 activation pathway, however, the downstream gene regulation in LMP1-expressing cells is still unclear.
Ugene, a binding partner of uracil DNA glycosylase, has been recently found to be an overexpressed protein in many kinds of cancers (Guo et al., 2008) , and suggested to have a role in tumor formation and promotion, but its cellular function and oncogenic activity are still unclear. In the initial screenings of LMP1-targeted genes in LMP1-transfected NPC cells, Ugene was identified to be highly inducible by LMP1, and hence designated herein as LMP1-induced protein (LMPIP). Evidence is provided herein that LMPIP was found to be a small organelle/membrane protein and colocalized with mitochondria. Endogenous LMPIP was inducible in peripheral blood mononuclear cells (PBMCs) infected with EBV and LMP1-transfected HEK 293 cells; also, LMPIP was found to be involved in the reactive oxygen species (ROS) metabolism and tumorigenic activity of LMP1 in NPC cells. Overexpression of LMPIP was also found in many EBVinfected cells and NPC patients in vitro and in vivo. These results suggested that in addition to its known function as a uracil DNA glycosylase-binding protein, LMPIP may have an important role in LMP1-induced tumorigenic effects.
Results

Induction of LMPIP (Ugene) expression by EBV infection and LMP1
To investigate the functional relationship between LMPIP and EBV (or LMP1) from previous microarray analyses of LMP1-transfected NPC tumor cells, PBMCs from healthy volunteers were infected with EBV virus (10 8 p.f.u./ml) and RNAs were collected from infected cells at different time points for the analysis of LMP1 and LMPIP gene expression ( Figure 1a ; lower panel). The mRNA and protein levels of LMPIP and LMP1 were analyzed with the use of real-time PCR and western blot, respectively. The LMP1 mRNA expression showed a time-dependent increase after EBV virus infection ( Figure 1a , red curve). LMPIP mRNA levels also increased, in a time-dependent manner, from 8 h after EBV infection. LMPIP protein expression level was slightly increased from 8 h after EBV infection ( Figure LMP1 is one of the important oncogenes of EBV and has been shown to be able to activate many cellular signaling pathways through different motifs, resulting in modification of the cell cycle and protection of cells from apoptosis. To further characterize the regulatory activity of LMP1 on the expression of LMPIP, different truncated forms of LMP1 gene constructs ( Figure 2a ) were transfected into HEK 293 cells and the expression of LMPIP was then analyzed. As seen in Figure 2b (left panel), LMPIP protein could be induced by wild-type LMP1 (247%), but LMP1 mutants with CTAR1 domain deletion (LMP1 D189-322 and D189-222), were not able to induce the expression of LMPIP (Figure 2b , right panel). Moreover, induction of LMPIP expression 
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by LMP1 was dependent on LMP1-induced activation of mitogen-activated protein kinase and nuclear factorkB, as LMP1-induced LMPIP expression could be inhibited by U 0126 (5 mM), a specific mitogen-activated protein kinase (extracellular signal-regulated kinase 1/2) signaling pathway inhibitor, and BAY 11-7085 (10 mM), a specific inhibitor of nuclear factor-kB signaling pathway ( Figure 2c ).
Characterization of LMPIP expression in adult mice and cellular localization
The LMPIP gene is located on chromosome 1q32 and encodes a mature protein with 149-amino acid length (16.6 kDa) with no identifiable conserved domains, but appears to be highly conserved among various species (Supplementary Data 1A and B) . Further, two genomic copies (chromosome 1p11 and 1q21) with high similarity in sequence (FAM72B and D) were blast searched and presented in Supplementary Data 1D.
To characterize the cellular function of LMPIP, anti-LMPIP polyclonal antibody was produced and the expression patterns of LMPIP in a variety of adult mouse tissues and cell lines were analyzed by immunohistology, immunofluorecence and western blotting. As shown in Figure 3a , LMPIP protein could be detected in several adult mouse tissues, including stomach with relatively high expression level, and kidney and heart with relatively low expression level. In the stomach, LMPIP was highly expressed in foveolar cells, parietal cells and chief cells (Figure 3b ), however, in kidney, LMPIP was found to be expressed in endothelial cells, mesangial and epithelial cells (parietal and visceral epithelium) around glomerulus (Figure 3b ; arrow).
To examine the subcellular localization of LMPIP, HEK 293 cells (with endogenous LMPIP expression) were sub-fractioned into four parts, including cytoplasm, organelle/membrane, nucleus and cytoskeleton, and stained with anti-LMPIP polyclonal antibody, followed by western blotting analysis. The results showed that two patterns of general localization of LMPIP could be observed in cells. One is dot-shaped distribution (Figure 3d middle panel) and another is of a lesser degree of dot-shaped aggregate replaced with more organelle (mitochondria, red color) localization (Figure 3d , lower panel (orange color)). A similar expression pattern was found in cells transfected with mouse LMPIP. These results were confirmed by immunofluorecence analysis with confocal observation.
It was noted that a fraction of intracellular LMPIP was found to be associated with mitochondria (red) around the nuclei, representing about 5.2-7.2% of total LMPIP, but LMPIP did not appear to be colocalized with Golgi/ER organelles (Figure 3d ).
LMPIP decreased cellular ROS production and mitochondria membrane potential (Dc) The colocalization expression pattern with mitochondria suggested LMPIP seemed to participate in energy metabolism and ROS generation regulation. To address the possibility, the cellular ROS content induced by H 2 O 2 (100 mM) treatment for 6 h in NPC cells (TW01 and HONE1) transfected with vector or human influenza hemagglutinin (HA)-tagged LMPIP were determined by 2 0 ,7 0 -dichlorfluorescein-diacetate (DCFH-DA) fluorescence staining (Figure 4a ). NPC cells transfected with LMPIP showed a decrease (84 and 71.5%, respectively) in ROS production induced by H 2 O 2 treatment comparing with mock-transfected cells (Figures 4a and b) . The ROS regulatory activity of LMPIP was further evalu- Moreover, analysis of LMPIP-transfected NPC cells showed that when compared with those with vector only, enhanced levels of expression for several cell cycle activators in G1/S phase were found, notably cyclin D1 (75.33%), E2F1 (229.67%), CDK2 (28.33%) and CDK4 (99.33) (Figure 5b ). The expression of tumor suppressors, including p16 (213.33%) and p21 waf/Cip (109.33%), also showed an increase over that of vector only, while the levels of p19 (14.33%) and RB (61.33%) were decreased compared with vector only (Figure 5c ). The levels of total p53 in LMPIP-transfected NPC cells showed modest increase (14.21%) as compared with those with vector control (Figure 5c ).
LMPIP expression was essential for the survival of NPC tumor cells
In addition to determining the effect on the cell cycle time course in G1/S transition, LMPIP's contribution to NPC tumorigenic effect was further evaluated with gene-specific short hairpin RNA interference (shRNAi) knock down. Two separate shRNAi sequences (145-165 and 1066-1086 bp) for LMPIP were sub-cloned into H1 promoter-driven vector and transfected into NPC cell lines, HONE1 and TW01 (Figure 6a ). Both of the Ugene (LMPIP) mediates LMP1-induced tumorigenesis L-T Wang et al two shRNAi constructs could effectively knockdown LMPIP expression by >85% (Figure 6a ). The NPC cells knocked down with shRNAi were then treated with H 2 O 2 (100 mM) for 6 h to evaluate the ROS regulation activity of LMPIP. The NPC cells transfected with LMPIP shRNAi showed an increase in cellular ROS production (103 and 91%, respectively) compared with those transfected with vector only (Figures 6b and c) . The stable TW01 cells with LMPIP knockdown were then collected for cell cycle population assay with flow cytometry (Figure 6e) . The results showed that TW01 cells with LMPIP knockdown had the fractions of the In addition, two known G1/S phase regulators were further analyzed in TW01 cells with LMPIP overexpression and knockdown as compared with those with vector controls. As shown in Figure 6d , while the level of p21 CIP was increased in the cytoplasm and nucleus in LMPIP-transfected cells, it was significantly decreased in cells with LMPIP knockdown. Similarly, increased expression of another G1/S regulator, E2F1, was observed in LMPIP-transfected cells, with primary expression detected in the nucleus, whereas lower level of E2F1 expression was detected in the cytoplasm fraction of LMPIP-knockdown cells. Further, the E2F1-binding protein, RB, was decreased in LMPIP-transfected cells and showed the same expression level in cells with LMPIP knockdown (Figure 6d) . These results suggested, beside CDKs and cyclin D, E2F1-involved signaling pathway was activated and participated the cell cycle activation in LMPIP overexpressed NPC cells.
The proliferative, transforming and tumorigenic activity of TW01 cells with LMPIP knockdown was further determined with [H 3 ] thymidindine incorporation, soft agar anchorage-independent growth assay in vitro and nude mice assay in vivo. TWO1 cells transfected with mock, LMPIP and LMPIP shRNAi were treated [H 3 ] thymidine (1 mM) in the medium for 18 h and the proliferation activity was analyzed with incorporated [H 3 ] thymidine in the genomic DNA. As shown in Figure 6f , cells with LMPIP knocked down by shRNAi indeed showed lower proliferation activity (15%) as compared with that noted in mock controls, and this effect was independent of LMP1 expression. Comparing with mock-transfected TWO1 cells, LMPIP expression cells showed an increase in proliferation activity (21%). NAC (N-acetyl-L-cysteine; 5 mM), an anti-oxidant chemical, could increase the cellular proliferation activity in TWO1 cells with or without LMPIP transfection. Further, in LMPIP shRNAi cells, NAC showed a dose-dependent increase in cell proliferation activity. These results suggested that LMPIP participates in cell growth regulation, and that LMP1's tumorigenic activity may be mediated, in part, by its inducing effect on the expression of LMPIP.
The LMP1 and LMPIP expression levels in different TW01 cells were determined with Western blot (Figure 6g ). As Figure 6h showed, overexpression of LMPIP in TW01 cells, as an ectopic LMP1 expression, significantly increased their transforming activity in soft agar assay (159±10.42 to 302±19.02 foci), however, the colony foci were dramatically decreased in TW01 cells with LMPIP knockdown (159 ± 10.42 to 36.60 ± 11.63) compared with vector-transfected cells. This was noted in cells with or without the expression of LMP1. For analysis of tumorigenic activity in vivo, TW01 cells (10 6 ) transfected with either vector, LMP1 or shRNAi constructs for LMP1 or LMPIP were injected into the abdomen and the back of nude mice (Figure 6i ). The tumor growth curve is shown in Figure 6i . When the tumor growth curves were compared, the tumor size in 
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mice receiving cells with LMPIP knockdown was smaller than those of mice receiving mock controls, or LMP1-transfected cells (Figure 6i ). Mice were killed at 6 weeks after inoculation and tumor cells were collected to detect LMPIP expression by western blot (Figure 6i ). The expression of LMPIP was still undetectable in TW01 cells with LMPIP knockdown until 6 weeks after injection. The same results were also obtained with HONE1 cells after LMPIP shRNAi knock down.
LMPIP overexpression was detected in EBV-infected NPC tumor mass
In order to clarify the effects of LMPIP overexpression on NPC cells and whether LMPIP has an important regulatory role in NPC tumor formation, several tumor cell lines were used to detect LMPIP expression. As showed in Figure 7a , many EBV-infected and NPC tumor cell lines have high LMPIP expression, such as BJAB (EBV-negative), Raji (EBV-positive), K562 and HL-60, with less expression seen in EBV-1 and 2 (PBMC from acute EBV-infected patients) comparing with the PBMC from healthy volunteers (Figure 7a ). To investigate the expression pattern of LMPIP in primary NPC cells, we also collected pairs of samples of normal and NPC tumor mass specimens from seven patients (EBV infected) to detect the LMP1 and LMPIP mRNA expression (Figure 7b ). The surgical NPC samples used in this study were relatively homogenous, and in all cases, contained o15% of the infiltrating cells, which were primarily the mononuclear cells. In five of seven subjects, cells obtained from NPC tumor mass samples showed that the LMPIP mRNA was overexpressed in tumor cells compared with their normal counterparts ( Figure 7b , upper and middle panel), while the levels of LMP1 expression were significantly higher in all tumors than those seen in their normal counterparts (bottom panel). One patient showed no difference in LMPIP mRNA expression in both normal and tumor-derived cells, and another showed lower LMPIP mRNA expression in tumor mass than in normal tissue. In order to examine whether the mRNA upregulation in tumor mass is coupled to protein overexpression, the LMPIP expression in tumor mass was further analyzed with immunohistochemistry with anti-LMPIP polyclonal antibody. LMPIP expression in undifferentiated ( Figure 7c ) and non-keratinizing NPC carcinoma (arrow) (Figure 7d ) with high LMPIP protein expression was also highly detected in the respective tumors (Figures 7c and d) . Further, the LMPIP protein in EBV-positive tumor mass showed a higher expression level than EBV-negative tumor mass in both types of NPC tumors (Figures 7c and d) .
Discussion
Ugene (FAM72A) or LMPIP, originally discovered following the screenings of differential gene expression in cancer cells, has been found to be highly expressed in most malignant tumor types, particularly in malignant colon cancers. Interestingly, Guo et al. (2008) showed that Ugene-encoded protein is localized in the nucleus and interacts with uracil DNA glycosylase 2, a base excision repair enzyme involved in DNA repair pathways, the alteration of which has often been noted in cancers. These results suggested the potential involvement of Ugene in tumorigenesis; however, as the investigators noted, when tested in epithelial or fibroblasts, no oncogenic activity of Ugene could be demonstrated and no apparent influence on the regulation of uracil DNA glycosylase 2 repair activity was found in vitro. In this study, the results showed that the Ugene (LMPIP) is an inducible downstream gene for EBV (LMP1) signaling and has a role in EBV (LMP1)-induced tumorigenic activity, suggesting a novel function of LMPIP. It has been established that many powerful oncoproteins, including LMP1 (Kanegane et al., 2002; Munz and Moormann, 2008) , are expressed in the latent stage of EBV infection. LMP1 protein is a ligand-independent tumor necrosis factor receptor, which can activate many mammalian signal transduction pathways mediated by three activation regions, 1, 2 and 3 (CTAR1, CTAR2 and CTAR3), in the C-terminal (Pai and Khanna, 2001; Kieser, 2008; Munz and Moormann, 2008) . Among them, CTAR1 domain has a critical role in LMP1-induced tumor transformation and accelerates G1/S transition in NPC cells through activation of nuclear factor-kB and mitogen-activated protein kinase signaling and upregulated expression of cell cycle regulators, such as CDK4, cyclin D1, E2F1 and survivin (Tsao et al., 2002; Ai et al., 2005; Soni et al., 2007; Zheng et al., 2007; Demetriades and Mosialos, 2009) , although the detailed mechanisms remain elusive. In this study, we found that LMPIP was one of the important mediators of LMP1 leading to decreased cellular ROS generation and shortened G1/S phase transition through the mitogen-activated protein kinase (extracellular signal-regulated kinase 1/2) and nuclear factor-kB signaling pathways. Further, the cells with LMPIP overexpression showed multiple protein activation similar to that of LMP1-transfected cells, specifically CDK4, cyclin D1, cyclin B1 and E2F1. These results suggested the possible involvement of LMPIP in LMP1-induced tumorigenesis.
Moreover, Ugene (LMPIP) has been shown to have a regulatory role in multiple cellular functions and specifically, in this study, in the regulation of cellular ROS metabolism. The cellular ROS are primarily produced intracellularly by two metabolic sources: the mitochondrial electron-transport chain and oxygenmetabolizing enzymatic reactions in mitochondria, such as xanthine oxidases, the cytochrome P450 system and NADPH oxidases (Bredt et al., 1991; Sauer et al., 2001; Sarsour et al., 2009) . ROS were traditionally thought of as toxic byproducts in cells, which damaged cellular macromolecules and led cells to apoptosis (Shackelford et al., 1999) . However, in recent years, several studies have shown that ROS can function as signaling molecules that regulate numerous cellular processes, including proliferation (Sundaresan et al., 1995; Behrend et al., 2003; Menon and Goswami, 2007; Bartosz, 2009 ). This dual function of ROS is based on differences in their concentrations, pulse duration and subcellular localization (Laurent et al., 2005; Bartosz, 2009) . High concentration of ROS in G1/S phase led to cell senescence or apoptosis and, on the contrary, low ROS facilitated cell cycle progression and activation of cell cycle regulators, such as, CDK4/6, cyclin D1, RB, p21 and E2F1 (Laurent et al., 2005; Menon and Goswami, 2007; Sarsour et al., 2009) . The cell cycle regulation involved in the enhancement of proliferation seems to be mediated by the increase in phosphorylation and thiol-redox reaction induced by many mitochondrial proteins, such as MnSOD (Sakamaki et al., 2006; . ROS stress seems to show a contrasting effect between normal and tumor cells. In normal mammalian cells, such as NIH 3T3 cells, a transient increase in cellular prooxidant levels in G1 is required for entry into S phase (Menon et al., 2003) . Inhibition of this prooxidant event with an antioxidant like (NAC) will inhibit progression from G1 to S and decrease cell proliferation. NAC-induced inhibition of entry into S phase was associated with an increase in MnSOD activity that showed a decrease in cyclin D1 protein levels . In tumor cells, antioxidant effect of NAC always decreases mitochondria-mediated ROS generation with subsequent decrease in cancer apoptosis. In this study, we also found that decreasing cellular ROS, for example, by the addition of NAC and overexpression of LMPIP, also increased cell proliferation activity. The detailed regulatory mechanisms by which mitochondrial proteins affect cell cycle progression are still unclear. Many studies have also demonstrated that LMP1 expression increased cellular ROS stress (Yu et al., 2002) , but did not lead tumor cells to apoptosis or senescence, which suggested that proteins involved in decreasing cellular ROS stress were activated after LMP1 expression. In this study, we showed that the regulation of the ROS metabolism by LMPIP facilitated the acceleration effect on cell cycle and tumorigenic activity of LMP1.
Two patterns of general localization of LMPIP were observed in cells. One was dot-shaped distribution (Figure 3d middle panel) and another was associated with organelle (mitochondria, red color) with a lesser degree of dot-shaped aggregate distribution (Figure 3d , lower panel (orange color). The exact regulatory mechanism of these changes in localization is still being evaluated. Moreover, the mitochondrial localization of LMPIP protein detected in purified mitochondria suggested that a portion of intracellular LMPIP was, indeed, associated with mitochondria. Also, overexpressed LMPIP was shown to directly decrease cellular ROS (DCFH2-DA staining) and protected MMP (Dc) suggesting that LMPIP is involved in the regulation of mitochondrial function. This mitochondrial-mediated ROS regulation resulted in a decreased cell population in G1/S phase and activation of G1/S check point regulators and further provided evidence that LMPIP could accelerate cell cycle progression through decreased cellular ROS concentration induced by LMP1 expression. Further work is needed to elucidate the functional significance of this association.
Taken together, these results suggest that LMPIP is an important downstream candidate of LMP1-induced pro-oncogenes participating in two regulatory pathways to shorten the cell cycle G1/S transition. First, LMPIP decreased cellular ROS level, which activated many G1/ S phase transition regulators in NPC tumor cell lines, such as CDKs and cyclin D proteins. It has been shown that the overexpression is closely associated with tumor cell G1/S checkpoint acceleration and malignant cell proliferation. Further, LMPIP may shorten G1/S transition through a decrease in pocket protein (RB) expression. Many studies also showed oxidative stress decreased RB phosphorylation, which blocked E2F1 release and the activation of G1/S regulators (Esposito et al., 2001; Tanaka et al., 2002) . In this study, it was found that in LMPIP-transfected NPC cells, cyclin D and CDK were activated and higher levels of E2F1 expression were also detected, with concurrent decrease in RB expression. Also, in LMPIP-transfected cells, a higher percentage of total RB was localized in the cytoplasm and most of the E2F1 was localized in the nucleus, suggesting that more E2F1 was released from RB binding and moved into the nucleus to activate downstream target gene transcription. It is tempting to speculate that LMPIP may be involved in this process. Further detailed work is needed to test this hypothesis. In this study, we also found p16 and p21 waf/CIP , but not p19 (down regulated), was increased in LMPIP-transfected NPC cells. Both p21
waf/CIP and p16 are oxidation and replication stress induced tumor suppressors and involved in senescence or apoptosis (Esposito et al., 2001; Burhans and Heintz, 2009) .
It is noted, however, that there is a set of highly related genes in the FAM72 family in the human genome; in fact, two genomic copies of FAM72 B and D are found. While our current emphasis is focused on FAM72A (Ugene), it is uncertain, at present, as to whether additional members of the FAM72 family are functionally divergent or show similar function to LMPIP (Ugene, FAM72A), which awaits further studies. Also, the results from our current studies of LMP1-induced Ugene in the context of EBV infection and NPC are at variance with those found in the original discovery of Ugene (Guo et al., 2008) . The reasons for this difference are currently unknown, but it is tempting to speculate that the different results may be the result of our emphasis on the initial steps in the induction of Ugene expression and function as a consequence of EBV infection or LMP1 overexpression, rather than being on the 'stationary' phase in the existing tumor cells. It is likely that the temporal-spatial features in Ugene's localization and function may follow a dynamic change as a consequence of activation and/or cellular transformation. It is the subject of further investigation, and our current study and others may provide a foundation for testing such an exciting possibility.
Taken together, the current results provide evidence supporting a novel role of LMPIP (Ugene) as an important mediator in LMP1-induced epithelial cell transformation and tumorigenesis.
Materials and methods
Plasmids and cell culture LMPIP (Ugene; FAM72A) full-length complementary DNA (accession number NM_175382) was cloned from mouse heart complementary DNA library (Stratagene, Santa Clara, CA, USA) and then sub-cloned into pEGFP N3 tagged with enhanced green fluorescent protein and pCDNA3 vector (Invitrogen Taiwan Ltd., Taipei, Taiwan). Latent phase genes of EBV including Zta, LMP1, LMP2A, LMP2B. EBNA1, EBNA2, BGLF4, EBNA3C and truncated LMP1 genes (DX, DT, DBX, DS, D189-222, D189-321 and D350-389) were also sub-cloned into pSG5 expression vector (Liebowitz et al., 1992; Liu et al., 2005) . The shRNAi sequences were shown as follows: 145-165, 5 0 -CTCCACTCCCTTCTCCAAAAG-3 0 and 1066-1086, 5 0 -CTGCCCAGTGTAGGTGTATTC-3 0 . TW01 and HONE1 cells, human NPC cell lines, were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Liu et al., 2005; Fang et al., 2009 ).
Preparation of LMPIP polyclonal antibody
Anti-LMPIP antibody was raised in New Zealand rabbits according to the protocol described by Hsu et al. (2001) . Keyhole limpet hemocyanin (KLH)-conjugated LMPIP peptide (91-102 a.a.) was used to immunize the rabbits and anti-LMPIP sera were collected and purified with bovine serum albumin-conjugated LMPIP peptide (91-102 a.a.) sulfoLink coupling column (PIERCE, Rockford, IL, USA).
EBV virus infection
EBV was purified from B95-8, a EBV producing marmoset cell line, treated with tissue plasminogen activator (TPA)/sodium butarate as in a previous study (Miller and Lipman, 1973) . EBV infection was carried out as described in the previous study (Chang et al., 1998) .
Total RNA extraction PBMCs from healthy volunteers and patients and NPC tumor samples were collected according to Approval of Clinical Trial (KMUH-IRB-950268). Total RNA was isolated from different cells transfected with different constructs or tumor mass and extracted with Trizol reagent (GIBCO/BRL, Grand Island, NY, USA) as previously described (Hsu et al., 2005) and mRNA was extracted with mRNA extraction kit (Qiagen, Valencia, CA, USA).
Immunofluorescence analysis
The cellular localization of LMPIP expression was determined by immunofluorescence as previously described (Hsu et al., 2004 (Hsu et al., , 2005 . TRIAC-conjugated Brefeldin A (Invitrogen Taiwan Ltd.) staining for Golgi apparatus and endoplasmic reticulum (ER) was performed as per the manufacturer's protocol.
Western blot and immunohistochemical staining analysis
Western blot analysis and immunohistochemical staining were performed as described (Hsu et al., 2001 (Hsu et al., , 2004 (Hsu et al., , 2005 . Other primary antibodies used in this study were b-actin polyclonal antibody (1:2000, Santa Cruz, Santa Cruz, CA, USA, I-19), hsp-70, cadherin, vimentin, CDK4, CDK2, CDK1, cyclin B1 and B23 polyclonal antibody (1:2000, Santa Cruz), p16, p19, cyclin D1, D3, p53, E2F1 and RB monoclonal antibodies (1:2000, Calbiochem, A Brand of EMD Biosciences, Inc., San Diego, CA, USA), histone 1, p21 CIP , p27, extracellular signalregulated kinase 1/2 and phospho-p53 ser15 antibodies (1:500, Cell Signaling Technology, Inc., Danvers, MA, USA), fluorescein isothiocyanate-conjugated anti-mouse, alkaline phosphataseconjugated anti-rabbit antibodies (1:500, Jackson ImmunoResearch Laboratory, West Grove, PA, USA) and LMPIP rabbit polyclonal antibody (1:5000, produced in-house).
Quantitative real-time PCR The LMPIP mRNA expression from PBMC, HEK 293 and tumor mass from NPC patients was detected by SYBR Green Quantitative RT-PCR kit (Invitrogen Taiwan Ltd.) as previously described (Hsu et al., 2005) . Two sets of primer sequences used to amplify the human LMPIP complementary DNA were: set1: LMPIP 1, 5 0 -AAATCCCACACCTCATC CTTCC-3 0 and LMPIP 2, 5 0 -CAGCAAAACAGCCTTCATT CCC-3 0 ; set2: LMPIP 3, 5 0 -TCCTGTCTTCTTTCCTGCAA, LMPIP 4, 5 0 -TGTAAACGTCCTACTTTGGG-3 0 . NPC tumor mass specimens from NPC patients were obtained according to the Institutional Review Board's protocol (KMUH-IRB-950268) and simply dissected using an anatomy microscopy. The NPC tumor samples contained o15% of infiltrating mononuclear cells.
Quantitative analysis of intracellular ROS Production of ROS was analyzed by flow cytometry as described previously (Hour et al., 2010) .
MMP (Dc) assays MMP levels were measured by the lipophilic cation JC-1 (5, 5 0 , 6, 6 0 -tetrachloro-1, 1 0 , 3, 3 0 ,-tetraethylbenzimidazolylcarbocyanine iodide) fluorescent dye (Smiley et al., 1991) .
Anchorage-independent growth assays Cells (1 Â 10 4 ) in 1-ml culture medium were mixed with an equal volume of 0.6% of top agar and plated onto 60-mm dishes with 0.5% bottom agar. Plates were incubated at 37 1C for 2 weeks. Colonies were visualized by staining with 0.05% crystal violet acetate and colonies larger than 0.5 mm were counted. The culture medium was refreshed every 3 days.
Tumor growth in nude mice
Female BALB/c nu/nu mice were obtained from the National Laboratory of Animal Breeding and Research Center (Taipei, Taiwan). Nude mice were inoculated (subcutaneous injection) with 1 Â 10 6 vector-or LMPIP shRNAi-transfected cells individually on either side of the back (n ¼ 10 mice per group). Tumor size was measured with a caliper once a week. The tumor volume was estimated according to the formula: volume (mm
, where L and W are the length and width of the tumor, respectively.
Statistical analysis
The quantitative results in this study are shown as means ± s.d. Statistical significance of two-way difference was assessed by Student's t-test.
